article thumbnail

STAT+: Documents detail how pharmacy giants Walgreens, CVS, and Walmart failed patients in the opioid epidemic

STAT

In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the country already awash in prescription painkillers, the federal government was demanding accountability from the pharmacy giant for filling thousands of opioid prescriptions written by doctors in suspiciously large quantities.  

article thumbnail

SAEM Clinical Images Series: Fever with Rash

ALiEM - Pharm Pearls

Fever was documented to be 102°F and was not associated with any chills or rigors. 2011 Oct 18;183(15):E1152. Epub 2011 Sep 12. A 40-year-old male, tailor by occupation, was brought to the Emergency Department with complaints of high-grade fever for the past 11 days. Curr Infect Dis Rep. 2009 Jan;11(1):66-72. PMID: 19094827.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

510(k) Modernization 2023

FDA Law Blog: Biosimilars

Lenz, Principal Medical Device Regulation Expert — On September 6, 2023, FDA announced its latest efforts to modernize the 510(k) process, outlining FDA’s latest improvements to strengthen the 510(k) Program and announcing release of three draft guidance documents.

article thumbnail

Novartis agrees $245m settlement over Exforge generics delay

pharmaphorum

The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed to keep Par’s generic version of the drug off the market until 30 September, 2014.

article thumbnail

Case Study 3 – Expert Regulatory Affairs Services for a European-Based Client

Syner-G

In 2011, following referral from another company, IMPACT (now part of Syner-G BioPharma Group) was contacted by a small development stage pharmaceutical company located in the United Kingdom to assist them with pre-IND activities for a new chemical entity for the treatment of asthma. Authored the client’s Pre-IND Briefing Document.

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Having worked for CROs since graduating, Sophie joined Pfizer in 2011 and has had various roles within the UK and now global groups. She holds a Bachelor’s degree in Biological Sciences and a PhD in Molecular Biochemistry from the University of Reading, UK. He has participated in four interventional studies and nine others.

article thumbnail

Tribunal maintains Lexon’s £1.2m fine for breaking competition law

pharmaphorum

That period was preceded by several years in which the price of nortriptyline had been rising dramatically, with NHS spending on the drug escalating from just over £6 million in 2011 to £38 million in 2015.